PAVmed Inc. (PAVM) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
PAVM Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, PAVmed Inc. (PAVM) trades at a price-to-earnings ratio of 14.4x, with a stock price of $7.16 and trailing twelve-month earnings per share of $-0.29.
The current P/E is 1774% above its 5-year average of 0.8x. Over the past five years, PAVM's P/E has ranged from a low of 0.5x to a high of 1.0x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, PAVM trades at a 35% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, PAVM trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PAVM DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PAVM P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.9Lowest | 0.67Best | +817%Best | |
| $2B | 13.9 | - | +382% | |
| $98B | 21.1 | - | +31% | |
| $80B | 27.8 | - | +55% | |
| $109B | 34.0 | 2.29 | +8% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
PAVM Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $0.60 | $1.16 | 0.5x | -33% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $0.72 | $0.71 | 1.0x | +33% |
Average P/E for displayed period: 0.8x
See PAVM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PAVM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PAVM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPAVM — Frequently Asked Questions
Quick answers to the most common questions about buying PAVM stock.
Is PAVM stock overvalued or undervalued?
PAVM trades at 14.4x P/E, above its 5-year average of 0.8x. The 100th percentile ranking indicates a premium to historical valuation.
How does PAVM's valuation compare to peers?
PAVmed Inc. P/E of 14.4x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is PAVM's PEG ratio?
PAVM PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.